Wall Street analysts expect Uniqure NV (NASDAQ:QURE) to report earnings of ($0.75) per share for the current fiscal quarter, Zacks reports. Five analysts have issued estimates for Uniqure’s earnings. The lowest EPS estimate is ($0.79) and the highest is ($0.71). Uniqure reported earnings of ($0.57) per share in the same quarter last year, which suggests a negative year over year growth rate of 31.6%. The business is expected to issue its next quarterly earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Uniqure will report full-year earnings of ($3.01) per share for the current fiscal year, with EPS estimates ranging from ($3.21) to ($2.85). For the next financial year, analysts forecast that the firm will report earnings of ($3.36) per share, with EPS estimates ranging from ($4.09) to ($2.52). Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Uniqure.
Uniqure (NASDAQ:QURE) last posted its quarterly earnings data on Monday, April 29th. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.71) by ($0.03). The company had revenue of $1.14 million during the quarter, compared to the consensus estimate of $2.00 million. Uniqure had a negative net margin of 1,032.06% and a negative return on equity of 48.90%.
In related news, insider Christian Klemt sold 1,546 shares of the firm’s stock in a transaction that occurred on Tuesday, April 16th. The stock was sold at an average price of $57.18, for a total transaction of $88,400.28. Following the completion of the sale, the insider now directly owns 54,539 shares of the company’s stock, valued at approximately $3,118,540.02. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Philip Astley-Sparke sold 6,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $59.84, for a total value of $359,040.00. Following the sale, the director now directly owns 19,272 shares of the company’s stock, valued at $1,153,236.48. The disclosure for this sale can be found here. Insiders have sold a total of 88,922 shares of company stock valued at $5,605,629 over the last three months. 2.91% of the stock is owned by corporate insiders.
Several hedge funds have recently modified their holdings of QURE. Harvest Group Wealth Management LLC bought a new stake in shares of Uniqure during the 1st quarter worth approximately $26,000. Legal & General Group Plc lifted its stake in shares of Uniqure by 264.2% during the 4th quarter. Legal & General Group Plc now owns 965 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 700 shares during the last quarter. Kore Private Wealth LLC bought a new stake in shares of Uniqure during the 1st quarter worth approximately $30,000. Pearl River Capital LLC bought a new stake in shares of Uniqure during the 1st quarter worth approximately $32,000. Finally, SEI Investments Co bought a new stake in shares of Uniqure during the 1st quarter worth approximately $35,000. 60.12% of the stock is owned by hedge funds and other institutional investors.
NASDAQ:QURE opened at $75.55 on Thursday. Uniqure has a 1 year low of $21.98 and a 1 year high of $75.85. The company has a debt-to-equity ratio of 0.38, a quick ratio of 9.51 and a current ratio of 9.51.
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure.
Further Reading: What is a Special Dividend?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Uniqure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure and related companies with MarketBeat.com's FREE daily email newsletter.